SCHAUMBURG, Ill., Feb. 25, 2016 -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, announced the hiring of Frank Harmon as Executive Vice President, Global Operations. In this newly created role, Mr. Harmon will oversee Sagent's Global Operations including Product Development, R&D, Manufacturing, Supply Chain, Regulatory and Global Alliance Management, with oversight support of Quality Assurance. Mr. Harmon will report directly to Allan Oberman, Sagent’s Chief Executive Officer.
"Mr. Harmon joins Sagent at an exciting time as we begin to execute against our “Triple E” strategy which is focused on accelerating our growth and enhancing our operational performance,” said Mr. Oberman. "Frank's extensive experience in pharmaceutical manufacturing and operations, with a proven history of success operating multiple injectable facilities, improving margins and managing complicated supply chains, will play an important role in accelerating our long-term growth trajectory and capitalizing on the favorable market opportunities that we see as critical to long-term value creation.”
Mr. Harmon has close to 40 years of pharmaceutical operations experience with companies including Fresenius Kabi, Cardinal Health, and Aventis-Behring (formerly Centeon LLC). Most recently, he served as Vice President, Operations of Nesher Pharmaceuticals (“Nesher”), a wholly owned subsidiary of Zydus Pharmaceuticals, where he was responsible for all manufacturing and contract packaging operations for generic solid dose and oral liquid products. Prior to joining Nesher, Mr. Harmon served as Chief Operating Officer and Executive Vice President of Fresenius Kabi USA, where he was responsible for managing a global network of parenteral manufacturing facilities and its global supply chain including supply from some of Sagent’s current partners. He earned an MBA degree from St. Louis University and holds a bachelor's degree in Biology and Chemistry from Western Kentucky University.
About Sagent Pharmaceuticals
Sagent Pharmaceuticals, Inc., founded in 2006, is a leading provider of affordable pharmaceuticals to the hospital market. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
For Immediate Release SAGENT CONTACT: Jonathon Singer [email protected] (847) 908-1605


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 



